Axogen, Inc. (AXGN)
NASDAQ: AXGN · Real-Time Price · USD
30.89
-1.86 (-5.68%)
Mar 18, 2026, 11:52 AM EDT - Market open
Axogen Revenue
In the year 2025, Axogen had annual revenue of $225.21M with 20.21% growth. Axogen had revenue of $59.90M in the quarter ending December 31, 2025, with 21.25% growth.
Revenue (ttm)
$225.21M
Revenue Growth
+20.21%
P/S Ratio
2.52
Revenue / Employee
$362,071
Employees
622
Market Cap
535.62M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 225.21M | 37.87M | 20.21% |
| Dec 31, 2024 | 187.34M | 28.33M | 17.81% |
| Dec 31, 2023 | 159.01M | 20.43M | 14.74% |
| Dec 31, 2022 | 138.58M | 11.23M | 8.81% |
| Dec 31, 2021 | 127.36M | 15.06M | 13.41% |
| Dec 31, 2020 | 112.30M | 5.59M | 5.24% |
| Dec 31, 2019 | 106.71M | 22.78M | 27.13% |
| Dec 31, 2018 | 83.94M | 23.51M | 38.91% |
| Dec 31, 2017 | 60.43M | 19.32M | 46.99% |
| Dec 31, 2016 | 41.11M | 13.78M | 50.41% |
| Dec 31, 2015 | 27.33M | 10.51M | 62.52% |
| Dec 31, 2014 | 16.82M | 5.87M | 53.62% |
| Dec 31, 2013 | 10.95M | 3.26M | 42.33% |
| Dec 31, 2012 | 7.69M | 2.84M | 58.61% |
| Dec 31, 2011 | 4.85M | 1.85M | 61.41% |
| Dec 31, 2010 | 3.00M | - | - |
| Dec 31, 2009 | - | - | - |
| Dec 31, 2008 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Integra LifeSciences Holdings | 1.64B |
| Varex Imaging | 854.40M |
| Orthofix Medical | 822.31M |
| Avanos Medical | 701.20M |
| Bioventus | 568.09M |
| Tactile Systems Technology | 329.52M |
| Cytek Biosciences | 201.49M |
| SI-BONE | 200.93M |
AXGN News
- 10 hours ago - AMG TimesSquare Small Cap Growth Fund Q4 2025 Performance Insights - Seeking Alpha
- 11 days ago - Axogen, Inc. (AXGN) Presents at 47th Annual Raymond James Institutional Investor Conference Transcript - Seeking Alpha
- 21 days ago - Axogen Q4: EPS Miss Amid Biologics Transition - Seeking Alpha
- 21 days ago - Axogen, Inc. (AXGN) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 26 days ago - First Eagle Small Cap Opportunity Fund Q4 2025 Portfolio Review - Seeking Alpha
- 4 weeks ago - Axogen, Inc. to Participate in Multiple Upcoming Investor Conferences - GlobeNewsWire
- 5 weeks ago - Axogen, Inc. to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026 - GlobeNewsWire
- 6 weeks ago - Wasatch Micro Cap Fund Q4 2025 Performance Review - Seeking Alpha